Fortrea Holdings Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everybody. I'm Dave Windley with Jefferies Healthcare Equity Research. I cover the CRO space. I'm the old gray hair in that business. I've been around the block a little bit and just love to have the companies in that space in the public domain, for one, and coming to our conference, for two. I'm grateful that the Fortrea team is here. Anshul Thakral, the company's CEO for a little over a year now. He's been very, very busy. Jason Knoblauch, who's joined more recently as CFO. Thank you both for being here.
You bet. Thank you to the audience, both in person here and listening, for your attention.
Anshul, let's start on demand. For you, commercial excellence. The combination of an environment that is getting better and a commercial focus that you have improved and getting better has driven consistently solid book-to-bills for you. Talk about how you've seen that evolve, how that is manifesting in demand by customer cohort.
Sure. This is a customer, pharma and biotech, excuse me.
Just kind of the robustness and the, call it the completeness of the picture.
Sure. Happy to, Dave. First of all, it is nice to see you. Thanks for stopping the rain while we walked over from Hotel One to Hotel Two.
I wish I had that power.
I think the demand environment, when I met with you, I think it was a year ago or something like that, I started using words like cautiously optimistic. I think I am getting ready to drop the word cautiously off as an identifier there. I think we are getting into the middle of demand recovery here. What happened? We saw early phase work, phase I work pick up the fastest. That is where decision-making can be quickest. Sometime in middle of 2025, we started seeing the demand for healthy volunteer studies in phase I really pick up. Then we started seeing demand from biotech companies pick up as funding environment got better. I do not look at funding month-to-month. I try to look at it more of a trend line, like you do.
As that environment really started getting better, I would say probably November of last year, going into early part of this year, we saw biotech demand starting to pick up. Now, over the last several months, we have really seen biopharma demand also pick up. I think once the first company negotiated its agreements with the U.S. government, all of a sudden, R&D pipelines started to move again at what I would call getting closer to a normal clip. We sit here now, towards the end of 2026, and I feel comfortable that in the segments of the market that I look at, one being early phase, another being biotech, and another one being biopharma, we are seeing demand pick up across all three. I think biotech remains a growth driver in terms of percentage of growth. It seems to be accelerating and remains a growth driver.
I think 2027's going to be an interesting year for the industry. That's where I see it.
Excellent. Yeah, that's great. While we're on large pharma versus biotech, Sure this is going to, probably setting your early phase business aside, what's the relative size of opportunity?
Thinking about spending the sales force time, what's the payoff for the time Sure in terms of size?
Sure. I think, look, from a market perspective, the vast amount of dollars are getting spent by what I call biopharma, call it the top 30 or so company. But growth right now and innovation, I see a lot of that in biotech or the small to mid-size companies. I would say right now, I've got our time disproportionately focused in biotech. The reason being, in biopharma, these are long sales cycles. These are partnership agreements and partnership cycles, and they take time. The sales effort there looks different than a traditional RFP prosecution. What it looks like is building relationships, getting invited to partnerships, working a partnership construct, winning a partnership, and then it's really up to the operations team in putting the right proposals together, executing good work. That's what yields repeat business within biopharma. In biotech, that requires a lot more hand-to-hand sales interaction.
If you're asking me where am I putting my sales team and my commercial team's time, it's a little disproportionate. It's disproportionate not because one is a priority versus another. One requires a different approach than the other.
Got it. In that, in so much as your phrase that you use to focus the conversation on commercial excellence, in so much as that, I'm sure, is honing focus, maybe topgrading.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
